Medracet

Tramadol Hydrochloride and Paracetamol, the active ingredients in Medracet, are a combination opioid and non‑opioid analgesic presented as an oral tablet for oral use. It is indicated for the management of moderate to severe acute pain, including postoperative and musculoskeletal pain, in adult patients. GNH USA supplies Medracet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medracet is used as a combination analgesic to treat pain conditions that involve both nociceptive and neuropathic pathways. - Moderate to severe acute pain: provides rapid relief by targeting central pain pathways. - Post‑operative pain: helps control pain after surgical procedures, facilitating recovery. - Musculoskeletal pain: reduces discomfort associated with injuries, strains, and inflammatory conditions.

Adverse reactions may occur with any analgesic combination and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: transient sensation of light‑headedness. - Constipation: reduced bowel motility. - Headache: mild cranial discomfort. - Somnolence: increased sleepiness or fatigue. - Sweating: excessive perspiration.

Serious or Rare Side Effects: - Seizures: risk increases with high doses or interacting drugs. - Serotonin syndrome: may develop when combined with serotonergic agents. - Respiratory depression: especially in patients with compromised breathing. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: rare liver injury linked to paracetamol overdose. - Anaphylaxis: acute allergic response requiring immediate medical attention.

Before prescribing Medracet, clinicians should consider patient‑specific factors and monitor for potential risks. - Assess renal and hepatic function: adjust use if impairment is present. - Avoid in severe respiratory depression: may exacerbate breathing difficulties. - Use caution with CNS depressants: concurrent sedatives can increase sedation. - Monitor for signs of dependence or misuse: especially with prolonged therapy. - Store below 25°C: keep in the original pack, protect from moisture.

Medracet can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: may precipitate serotonin toxicity. - Alcohol or other CNS depressants: heightened sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): increase tramadol plasma levels. - Warfarin: paracetamol may enhance anticoagulant effect. - Anticonvulsants (e.g., carbamazepine): may lower tramadol efficacy.